KRYS Stock Forecast: Krystal Biotech, Inc. Price Predictions for 2026-2027
The 12 Wall Street analysts covering Krystal Biotech, Inc. hold a median 12-month price target of $380 — +23.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 83 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Krystal Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Accruals (42): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KRYS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KRYS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.2% from it.
Of the 20 most recent actions, 3 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | Citigroup | Maintains | Buy | $416 → $412 |
| 3 Nov 2026 | RBC Capital | Maintains | Outperform | $400 → $375 |
| 3 Nov 2026 | TD Cowen | Maintains | Buy | $403 → $380 |
| 15 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $361 |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Buy | $441 |
| 21 Sept 2026 | B of A Securities | Maintains | Buy | $392 → $400 |
| 14 Aug 2026 | RBC Capital | Initiates | Outperform | $400 |
| 4 Aug 2026 | Citigroup | Maintains | Buy | $378 → $386 |
| 14 July 2026 | B of A Securities | Maintains | Buy | $364 → $396 |
| 18 June 2026 | TD Cowen | Maintains | Buy | — |
| 16 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2026 | Citigroup | Maintains | Buy | — |
| 5 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 4 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 25 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 18 Feb 2026 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KRYS.
This page is one stock. Monday covers all of them.
KRYS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KRYS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Krystal Biotech, Inc. returned +51.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KRYS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 43.5×
- Price / sales
- 20.2×
- Price / book
- 6.6×
- EV / EBITDA
- 36.9×
Cheaper than 19% of US stocks
Cheaper than 8% of US stocks
Cheaper than 12% of US stocks
Cheaper than 8% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −20.5%
- Gross margin
- 94.6%
- Operating margin
- 48.4%
- Net margin
- —
Higher than 20% of US stocks
Higher than 98% of US stocks
Higher than 96% of US stocks
- Return on equity
- 17.5%
- Return on assets
- 10.1%
- Dividend yield
- —
Higher than 78% of US stocks
Higher than 92% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Krystal Biotech, Inc. has a market value of $9.4B and an enterprise value of $8.5B.
Revenue in the twelve months to 30 June 2026: $440.5M. The latest quarter grew 24.1% year on year.
Net income over the same four quarters: $241.5M, a 54.8% net margin.
Diluted earnings per share, trailing twelve months: $7.98.
Free cash flow in the twelve months to 30 June 2026: $257.8M.
Trailing P/E: 43.5×; forward P/E: 34.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Krystal Biotech, Inc. employs 295 people — $1.5M of revenue per employee.
Data provided by Twelve Data
KRYS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KRYS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Krystal Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KRYS
What is the KRYS stock price forecast for 2026-2027?
The 12 Wall Street analysts covering Krystal Biotech, Inc. have a median 12-month price target of $380, with estimates ranging from $284 to $474. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KRYS stock a buy right now?
Of the 12 analysts covering Krystal Biotech, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Krystal Biotech, Inc. 83 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KRYS?
As at 21 Nov 2026, Krystal Biotech, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
Will KRYS stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +23.2% from the last close, and Ticker Nerd's factor model ranks Krystal Biotech, Inc. 83 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KRYS stock forecast for 2030?
No analyst covering Krystal Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRYS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $284 to $474 over the next 12 months.
How has KRYS stock performed over the past year?
Krystal Biotech, Inc. returned +51.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Krystal Biotech, Inc. do?
Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases. Its lead product, VYJUVEK, is a redosable gene therapy approved for dystrophic epidermolysis bullosa, a rare inherited skin disorder.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases. Its lead product, VYJUVEK, is a redosable gene therapy approved for dystrophic epidermolysis bullosa, a rare inherited skin disorder. The company’s work centers on its proprietary HSV-1-based delivery platform, which supports programs across dermatology, respiratory, ophthalmology, oncology, and aesthetics. Through this platform, Krystal Biotech develops therapies designed to address high unmet medical needs and expand treatment options in specialized disease areas. Headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a notable role in the gene therapy market by combining commercial operations with a broader pipeline of investigational genetic medicine candidates.
CEO Mr. Krish S. Krishnan M.B.A., M.S. · 295 employees · United States · https://www.krystalbio.com